Suppr超能文献

芪参益气滴丸对小鼠横断主动脉缩窄诱导的心力衰竭的心脏保护作用。

Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice.

作者信息

Ruan Guoran, Ren Haojin, Zhang Chi, Zhu Xiaogang, Xu Chao, Wang Liyue

机构信息

Department of Cardiology, The Puren Hospital, Wuhan University of Science and Technology, Wuhan, China.

出版信息

Front Physiol. 2018 Apr 3;9:324. doi: 10.3389/fphys.2018.00324. eCollection 2018.

Abstract

QiShenYiQi dripping pills (QSYQ), a traditional Chinese medicine, are commonly used to treat coronary heart disease, and QSYQ was recently approved as a complementary treatment for ischemic heart failure in China. However, only few studies reported on whether QSYQ exerts a protective effect on heart failure induced by pressure overload. In this study, we explored the role of QSYQ in a mouse model of heart failure induced by transverse aortic constriction (TAC). Twenty-eight C57BL/6J mice were divided into four groups: Sham + NS group, Sham + QSYQ group, TAC + NS group, and TAC + QSYQ group. QSYQ dissolved in normal saline (NS) was administered intragastrically (3.5 mg/100 g/day) in the Sham + QSYQ and TAC + QSYQ groups. In the Sham + NS and TAC + NS groups, NS was provided every day intragastrically. Eight weeks after TAC, echocardiography, and cardiac catheterization were performed to evaluate the cardiac function, and immunofluorescent staining with anti-actinin2 antibody was performed to determine the structure of the myocardial fibers. Moreover, TUNEL staining and Masson trichrome staining were employed to assess the effects of QSYQ on cardiac apoptosis and cardiac fibrosis. Western blots and real-time polymerase chain reaction (PCR) were used to measure the expression levels of vascular endothelial growth factor (VEGF) in the heart, and immunohistochemical staining with anti-CD31 antibody was performed to explore the role of QSYQ in cardiac angiogenesis. Results showed that TAC-induced cardiac dysfunction and disrupted structure of myocardial fibers significantly improved after QSYQ treatment. Moreover, QSYQ treatment also significantly improved cardiac apoptosis and cardiac fibrosis in TAC-induced heart failure, which was accompanied by an increase in VEGF expression levels and maintenance of microvessel density in the heart. In conclusion, QSYQ exerts a protective effect on TAC-induced heart failure, which could be attributed to enhanced cardiac angiogenesis, which is closely related to QSYQ. Thus, QSYQ may be a promising traditional Chinese medicine for the treatment of heart failure induced by pressure overload such as hypertension.

摘要

芪参益气滴丸(QSYQ)是一种传统中药,常用于治疗冠心病,最近在中国被批准作为缺血性心力衰竭的辅助治疗药物。然而,关于芪参益气滴丸是否对压力超负荷诱导的心力衰竭具有保护作用的研究报道较少。在本研究中,我们探讨了芪参益气滴丸在横断主动脉缩窄(TAC)诱导的小鼠心力衰竭模型中的作用。将28只C57BL/6J小鼠分为四组:假手术+生理盐水组(Sham + NS组)、假手术+芪参益气滴丸组(Sham + QSYQ组)、TAC +生理盐水组(TAC + NS组)和TAC +芪参益气滴丸组(TAC + QSYQ组)。在Sham + QSYQ组和TAC + QSYQ组中,将溶解于生理盐水(NS)的芪参益气滴丸灌胃给药(3.5 mg/100 g/天)。在Sham + NS组和TAC + NS组中,每天灌胃给予生理盐水。TAC术后8周,进行超声心动图和心导管检查以评估心功能,并用抗肌动蛋白2抗体进行免疫荧光染色以确定心肌纤维结构。此外,采用TUNEL染色和Masson三色染色评估芪参益气滴丸对心肌细胞凋亡和心肌纤维化的影响。使用蛋白质免疫印迹法和实时聚合酶链反应(PCR)检测心脏中血管内皮生长因子(VEGF)的表达水平,并用抗CD31抗体进行免疫组织化学染色以探讨芪参益气滴丸在心脏血管生成中的作用。结果表明,芪参益气滴丸治疗后,TAC诱导的心脏功能障碍和心肌纤维结构破坏明显改善。此外,芪参益气滴丸治疗还显著改善了TAC诱导的心力衰竭中的心肌细胞凋亡和心肌纤维化,同时伴有心脏中VEGF表达水平的增加和微血管密度的维持。总之,芪参益气滴丸对TAC诱导的心力衰竭具有保护作用,这可能归因于其增强的心脏血管生成,这与芪参益气滴丸密切相关。因此,芪参益气滴丸可能是一种有前途的传统中药,可用于治疗高血压等压力超负荷诱导的心力衰竭。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28dd/5891926/005ec362193f/fphys-09-00324-g0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验